Clinical trials: HIV 2 Infection
Cytomegalovirus Retinitis, HIV Infections
A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy
To compare the safety and tolerance of oral ganciclovir at a double dose 3 times/day or a single dose 6 times/day to IV ganciclovir given for 20 weeks of maintenance therapy.
- Trial name
- NCT00002247
- Testing
- Ganciclovir
- Where
- 20 sites in United States, Canada
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
HIV, HIV Infections
The First Failure Study
The purpose of this study is to look at two different antiretroviral treatment options in individuals who are about to commence their second antiretroviral treatment.
- Trial name
- FAST (NCT01118871)
- Testing
- Darunavir, Ritonavir, Truvada, Darunavir, Ritonavir and Etravirine
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London
HIV Infection
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
As a measure of secondary prophylaxis, and with the final objective of avoiding the infection, it has been suggested to use antiretroviral therapy. This is known as post-exposure prophylaxis (PEP).
- Trial name
- RAL-PEP (NCT01576731)
- Testing
- Tenofovir, Emtricitabine, Lopinavir/r, Tenofovir, Emtricitabine, Raltegravir
- Where
- Spain
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Healthy
Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers
The purpose of this study is to assess the safety and tolerability of 2 different dose levels of trimeric glycoprotein140 (gp140) administered as a 2-dosage regimen, intramuscularly (injection of a substance into a muscle), with…
- Trial name
- NCT02304185
- Testing
- gp140, 50 mcg, gp140, 50 mcg + Adjuvant, gp140, 250 mcg
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
HIV Infections
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA…
- Trial name
- NCT05674656
- Testing
- Dolutegravir/Rilpivirine FDC
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- ViiV Healthcare
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children
The primary objectives of Cohort 1 are to evaluate the steady state pharmacokinetics (PK) for elvitegravir (EVG) and tenofovir alafenamide (TAF) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir…
- Trial name
- NCT01854775
- Testing
- E/C/F/TAF, E/C/F/TAF (Low Dose)
- Where
- 16 sites in United States, South Africa and 3 more
- Volunteers
- 129 people
- Sponsor
- Gilead Sciences
Anemia, Neutropenia
Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin
This study is designed to test two separate strategies for treatment of anemia (low hemoglobin) and neutropenia (low white blood cells) in HIV/HCV coinfected patients who are being treated with pegylated interferon and ribavirin.
- Conditions
- Anemia, Neutropenia, Hepatitis C Virus, HIV Infections
- Trial name
- NCT00194857
- Testing
- erythropoietin, GCSF
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
HIV Infections
Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens
Collecting data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) after switching from protease inhibitor or NNRTI to Nevirapine (Viramune®) and collecting of…
- Trial name
- NCT02191319
- Testing
- Viramune®
- Volunteers
- 55 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Lipodystrophy
TH9507 in Patients With HIV-Associated Lipodystrophy
HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation and loss of extremity and subcutaneous fat, in…
- Trial name
- NCT00123253
- Testing
- TH9507
- Where
- 42 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Theratechnologies
HIV/AIDS, Meningococcal Disease
Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study
The need for and timing of booster doses of meningococcal vaccines in People Living with HIV (PLWHIV) is currently unknown. As such it is impossible for clinicians to recommend booster doses or to know if and when these might be…
- Trial name
- NCT04239430
- Testing
- Serum Bactericidal Assays
- Where
- United Kingdom
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
HIV Infections
Collection of Blood Samples From SMART Study Participants for Future Genetic Studies
The purpose of this study is to collect blood samples from SMART study participants to use in future genetic studies.
- Trial name
- NCT00377169
- Where
- 42 sites in United States, American Samoa and 14 more
- Volunteers
- 3,261 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Bioequivalency Study of Zidovudine Under Fed Conditions
The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg tablet compared to GlaxoSmithKline's Retrovir® 300 mg tablet under fed conditions using a single-dose, randomized, 2-treatment, 2-period…
- Trial name
- NCT00601562
- Testing
- Zidovudine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
HIV Infections
A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine
The purpose of this study is to make didanosine (ddI) available to children with AIDS who are clinically deteriorating on zidovudine (AZT) or intolerant to AZT and cannot enter the Phase II ddI programs due to protocol exclusion…
- Trial name
- NCT00002280
- Testing
- Didanosine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir
This study will compare the safety and effectiveness of two anti-HIV drug combinations in fighting HIV infection in patients whose viral loads (levels of HIV in the blood) rose with other anti-HIV drug treatments.
- Trial name
- NCT00002423
- Testing
- Indinavir sulfate, Abacavir sulfate, Amprenavir
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Glaxo Wellcome
HIV (Human Immunodeficiency Virus)
Boosting Olfactory and Sensory Training Study (BOOST)
The goal of this study is to examine two types of olfactory interventions (conventional olfactory training vs scented marker training) in adults with HIV. The two research questions are: 1.
- Trial name
- BOOST (NCT07221123)
- Testing
- Conventional Smell Training Group, Scented Marker Group
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Alabama at Birmingham
HIV Infections
Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age
The MONOD trial aim to evaluate the implementation of early antiretroviral treatment strategies in HIV-infected infants and assess the feasibility and efficacy of simplifying the initial proposed regimen after a successful one…
- Trial name
- NCT01127204
- Testing
- AZT-3TC-LPV/r twice a day, ABC-3TC-EFV once a day
- Where
- 4 sites in Burkina Faso, Côte d’Ivoire
- Volunteers
- 161 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient
To evaluate the safety and tolerance of the combination of adefovir dipivoxil at two comparative doses and nelfinavir plus saquinavir SGC administered orally (Group 1) vs.
- Trial name
- NCT00002184
- Testing
- Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus, Contraception
Investigating the Interaction Between Two Long-acting Reversible Methods of Contraception and Dolutegravir, a Treatment for HIV
It is important to make sure that women have access to effective methods of contraception to prevent pregnancy so that they can make choices about when and if they will have their first or next child.
- Conditions
- Human Immunodeficiency Virus, Contraception, ART
- Trial name
- CODA (NCT04910711)
- Testing
- Dolutegravir, Levonorgestrel implant, Depo medroxyprogesterone acetate injection
- Where
- Botswana
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Botswana Harvard AIDS Institute Partnership
Infection, Human Immunodeficiency Virus I
A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
This is a single-center, open-label, three-period, fixed-sequence cross over study in healthy adult subjects. A total of approximately 16 healthy subjects will be enrolled to provide data from 12 evaluable subjects.
- Trial name
- NCT01283100
- Testing
- GSK1349572, GSK2248761
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
To Determine if Chromium Nicotinate Supplementation Will Improve Insulin Resistance in HIV Patients With Metabolic Abnormalities
In HIV patients, fasting insulin levels decrease with chromium supplementation. This study is to determine if chromium nicotinate supplementation at 400ug/day for 16 weeks will improve insulin resistance in HIV patients with…
- Trial name
- NCT00152893
- Testing
- chromium nicotinate
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Johane Allard